Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venalar 500 is a dietary supplement (БАД) developed and manufactured by the Russian company Diod, specifically formulated to support venous health and address venous circulation disorders. It contains a micronized flavonoid fraction consisting of 450 mg of diosmin and 50 mg of hesperidin. The supplement acts as a venotonic and angioprotective agent; it increases venous tone by prolonging the activity of norepinephrine on the vessel wall, improves lymphatic drainage, and reduces capillary permeability and inflammation. It is commonly used to alleviate symptoms of chronic venous insufficiency, such as leg heaviness, pain, and nocturnal cramps, as well as for the symptomatic treatment of hemorrhoids. As a dietary supplement, it is not classified as a pharmaceutical medicinal product in Russia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Venalar 500.